Peter Schmidt

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman, Sally F. Barrington, David Belada et al. · The Lancet Oncology · 2018 · 152 citations · Full text

Lymphoid Neoplasia, End-of-induction Pet Response, Medicine +7

Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study

Ute Rupp, Eva Schoendorf-Holland, Michael Eichbaum et al. · Anti-Cancer Drugs · 2007 · 94 citations

Metastatic Breast Cancer, Oncology, Breast Oncology +10

Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Disease-free survival results at interim analysis.

Hans‐Joachim Schmoll, Karin Haustermans, Timothy Price et al. · Journal of Clinical Oncology · 2014 · 90 citations

Surgical Oncology, Cancer Management, Anal Verge +20

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

Mohamad Mohty, Evangelos Terpos, María‐Victoria Mateos et al. · Clinical Lymphoma Myeloma & Leukemia · 2018 · 89 citations · Full text

Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: First results of the PETACC-6 randomized phase III trial.

Hans‐Joachim Schmoll, Karin Haustermans, Timothy Price et al. · Journal of Clinical Oncology · 2013 · 63 citations

Surgical Oncology, Cancer Management, Anal Verge +18